Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | ERN1 | O75460 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20448832 | 0.90 | TSHR (0.49) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL78317 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL29953040 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL4303573 | 0.82 | TSHR (0.57) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL9463305 | 0.82 | ERN1 (0.55) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL9190390 | 0.80 | ERN1 (0.49) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL9790002 | 0.80 | ERN1 (0.67) | SMN1; SMN2TSHRCASP1ERN1ALDH1A1 | |
| SCHEMBL7069945 | 0.79 | TSHR (0.53) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL7069948 | 0.79 | TSHR (0.53) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL2420654 | 0.78 | ABL1 (0.60) | SMN1; SMN2ERN1ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11199543-A | — | — | None | — | — | JP | disclosed |
| JP-11199544-A | — | — | None | — | — | JP | disclosed |
| JP-11246542-A | — | — | None | — | — | JP | disclosed |
| CN-117486844-A | Green synthesis method of photo-promoted quaternary carbon center-containing phthalide derivative | 重庆医科大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-113336780-B | Preparation method of 2-formyl-4- (4-cyanophenoxy) phenylboronic acid pinacol ester | 山东省药学科学院 | 2023-02-17 | — | — | CN | disclosed |
| CN-113336780-A | Preparation method of 2-formyl-4- (4-cyanophenoxy) phenylboronic acid pinacol ester | 山东省药学科学院 | 2021-09-03 | — | — | CN | disclosed |
| EP-3356338-B1 | METHODS FOR SYNTHESIZING RHODAMINE DYES | PROMEGA CORP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10093806-B2 | Methods for synthesizing rhodamine dyes | PROMEGA CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3356338-A1 | METHODS FOR SYNTHESIZING RHODAMINE DYES | Promega Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170096560-A1 | METHODS FOR SYNTHESIZING RHODAMINE DYES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1581501-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1539701-A1 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004058718-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-15 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
| JP-H11246542-A | NEW DICHLOROPHTHALIDE AND ITS PRODUCTION, AND PRODUCTION OF 2-FORMYLBENZOIC ACID NUCLEUS CHLORINATION PRODUCTS USING THE SAME | NIPPON LIGHT METAL CO LTD | 1999-09-14 | — | — | JP | disclosed |
| JP-H11199543-A | PRODUCTION OF BENZENE NUCLEUS-CHLORINATED 2-FORMYLBENZOIC ACID | NIPPON LIGHT METAL CO LTD | 1999-07-27 | — | — | JP | disclosed |
| JP-H11199544-A | PRODUCTION OF BENZENE NUCLEUS-CHLORINATED 2-FORMYLBENZOIC ACID | NIPPON LIGHT METAL CO LTD | 1999-07-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072850-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP2 | SMN1; SMN2 655/4885TSHR 4796/4885CASP1 1/4885 |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | SMN1; SMN2 302/4885TSHR 3868/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.